Skip to main content
. Author manuscript; available in PMC: 2020 Dec 24.
Published in final edited form as: Nature. 2020 Jun 24;583(7817):609–614. doi: 10.1038/s41586-020-2422-6

Figure 4. DR-18 promotes NK cell maturation and polyfunctionality to treat MHC class I deficient tumors.

Figure 4.

(a) Kaplan-Meier survival curve of WT mice engrafted s.c. with MC38-B2m−/− tumors and treated twice weekly with PBS, anti-PD-1 plus anti-CTLA-4, IL-18, DR-18, or DR-18 plus anti-CD8 and anti-NK1.1 antibodies. (b,c) t-SNE projection showing Ncr1+ positive cells present in the YUMMER1.7 and YUMMER1.7-B2m−/− tumors colored by (b) unique cluster and (c) by treatment. (d) Heatmaps showing mean expression of curated genes for each of the NK cell clusters shown in (b). (e,f) Quantification of surface (e) KLRG1 and (f) CD27/CD11b staining by percentage on intratumoral NK cells from the indicated treatment groups. (g) Representative flow plots, (h) absolute numbers and (i) frequency of intratumoral polyfunctional NK cells measured by co-staining of intracellular IFN-γ and Granzyme B following ex vivo stimulation with PMA/ionomycin. Data are representative of 3 independent experiments with n=5 mice per group and presented as the mean ± SEM. P values were calculated using two-tailed unpaired Student’s t-tests (e) and Two-way ANOVA (f,h).